162 related articles for article (PubMed ID: 23260517)
1. [Topical treatment of hyperpigmentation disorders].
Rendon M; Horwitz S
Ann Dermatol Venereol; 2012 Nov; 139 Suppl 3():S102-7. PubMed ID: 23260517
[TBL] [Abstract][Full Text] [Related]
2. Topical treatment of hyperpigmentation disorders.
Rendon M; Horwitz S
Ann Dermatol Venereol; 2012 Dec; 139 Suppl 4():S153-8. PubMed ID: 23522631
[TBL] [Abstract][Full Text] [Related]
3. New and emerging treatments for hyperpigmentation.
Alexis AF
J Drugs Dermatol; 2014 Apr; 13(4):382-5. PubMed ID: 24719055
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of hydroquinone-free skin-lightening cream for photoaging.
Dreher F; Draelos ZD; Gold MH; Goldman MP; Fabi SG; Puissegur Lupo ML
J Cosmet Dermatol; 2013 Mar; 12(1):12-7. PubMed ID: 23438137
[TBL] [Abstract][Full Text] [Related]
5. 4-n-butylresorcinol, a highly effective tyrosinase inhibitor for the topical treatment of hyperpigmentation.
Kolbe L; Mann T; Gerwat W; Batzer J; Ahlheit S; Scherner C; Wenck H; Stäb F
J Eur Acad Dermatol Venereol; 2013 Jan; 27 Suppl 1():19-23. PubMed ID: 23205541
[TBL] [Abstract][Full Text] [Related]
6. Glutathione as a skin whitening agent: Facts, myths, evidence and controversies.
Sonthalia S; Daulatabad D; Sarkar R
Indian J Dermatol Venereol Leprol; 2016; 82(3):262-72. PubMed ID: 27088927
[TBL] [Abstract][Full Text] [Related]
7. Single blind, randomized, controlled trial of a lightening product with and without iontophoresis versus tretinoin and vehicle for hyperpigmentation.
Wanner M; Houston N; Javorsky E; Yuan M; Alora-Palli M; Kimball AB
J Drugs Dermatol; 2015 Jan; 14(1):13-8. PubMed ID: 25607903
[TBL] [Abstract][Full Text] [Related]
8. The role of systemic treatments for skin lightening.
Juhasz MLW; Levin MK
J Cosmet Dermatol; 2018 Dec; 17(6):1144-1157. PubMed ID: 30133125
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a hydroquinone-free skin brightening product using in vitro inhibition of melanogenesis and clinical reduction of ultraviolet-induced hyperpigmentation.
Makino ET; Mehta RC; Banga A; Jain P; Sigler ML; Sonti S
J Drugs Dermatol; 2013 Mar; 12(3):s16-20. PubMed ID: 23545928
[TBL] [Abstract][Full Text] [Related]
10. [Topical treatment of pigmentation disorders with cosmetic and pharmaceutical agents].
Kerscher M; Buntrock H
Hautarzt; 2020 Dec; 71(12):944-949. PubMed ID: 33146766
[TBL] [Abstract][Full Text] [Related]
11. Development, Characterization and Pharmacological Evaluation of Antiblemish Cream Containing Herbal Oils.
Krishnaraj S; Mahadevappa K; Narayanaswamy RM; Kamnoore D; Lingutla R; Ghosh T
Recent Pat Drug Deliv Formul; 2020; 14(3):223-232. PubMed ID: 32479252
[TBL] [Abstract][Full Text] [Related]
12. Split-Face Comparison of an Advanced Non-Hydroquinone Lightening Solution to 4% Hydroquinone.
Schlessinger J; Saxena S; Mohr S
J Drugs Dermatol; 2016 Dec; 15(12):1571-1577. PubMed ID: 28095580
[TBL] [Abstract][Full Text] [Related]
13. Topical treatments for melasma and postinflammatory hyperpigmentation.
Lynde CB; Kraft JN; Lynde CW
Skin Therapy Lett; 2006 Nov; 11(9):1-6. PubMed ID: 17075653
[TBL] [Abstract][Full Text] [Related]
14. Treatment of hyperpigmentation.
Rossi AM; Perez MI
Facial Plast Surg Clin North Am; 2011 May; 19(2):313-24. PubMed ID: 21763992
[TBL] [Abstract][Full Text] [Related]
15. Development and Clinical Assessment of a Comprehensive Product for Pigmentation Control in Multiple Ethnic Populations.
Makino ET; Kadoya K; Sigler ML; Hino PD; Mehta RC
J Drugs Dermatol; 2016 Dec; 15(12):1562-1570. PubMed ID: 28095579
[TBL] [Abstract][Full Text] [Related]
16. Accelerating bleaching in vitiligo: balancing benefits versus risks.
Seneschal J; Boniface K; Ezzedine K; Taieb A
Exp Dermatol; 2014 Dec; 23(12):879-80. PubMed ID: 25039467
[TBL] [Abstract][Full Text] [Related]
17. Tolerance and efficacy of a product containing ellagic and salicylic acids in reducing hyperpigmentation and dark spots in comparison with 4% hydroquinone.
Dahl A; Yatskayer M; Raab S; Oresajo C
J Drugs Dermatol; 2013 Jan; 12(1):52-8. PubMed ID: 23377328
[TBL] [Abstract][Full Text] [Related]
18. The assessment of the effect of a cosmetic product brightening the skin of people with discolorations of different etiology.
Zasada M; Debowska R; Pasikowska M; Budzisz E
J Cosmet Dermatol; 2016 Dec; 15(4):493-502. PubMed ID: 27349716
[TBL] [Abstract][Full Text] [Related]
19. A Topical Depigmentation Program Against Hyperpigmentation Enhances the Benefits of Previously Performed Chemical Peeling Procedures of the Face.
Cavallini M; Montanaro F; Papagni M
J Cosmet Sci; 2020; 71(6):385-397. PubMed ID: 33413783
[TBL] [Abstract][Full Text] [Related]
20. New and experimental treatments of cloasma and other hypermelanoses.
Picardo M; Carrera M
Dermatol Clin; 2007 Jul; 25(3):353-62, ix. PubMed ID: 17662901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
